Dr. Reddy's Laboratories - RDY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $67.00
  • Forecasted Upside: 24.74 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$53.71
▲ +0.46 (0.86%)

This chart shows the closing price for RDY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dr. Reddy's Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RDY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RDY

Analyst Price Target is $67.00
▲ +24.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Dr. Reddy's Laboratories in the last 3 months. The average price target is $67.00, with a high forecast of $67.00 and a low forecast of $67.00. The average price target represents a 24.74% upside from the last price of $53.71.

This chart shows the closing price for RDY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Dr. Reddy's Laboratories. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2022Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
10/31/2022BarclaysBoost TargetOverweight$66.00 ➝ $67.00Low
10/25/2022BarclaysLower TargetOverweight$69.00 ➝ $66.00Low
9/12/2022BarclaysBoost TargetOverweight$68.00 ➝ $69.00Low
5/24/2022BarclaysBoost TargetOverweight$69.00 ➝ $70.00Low
4/28/2022BarclaysLower Target$71.00 ➝ $69.00Medium
11/1/2021BarclaysBoost TargetOverweight$78.00 ➝ $80.00Low
7/27/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral$63.41Low
5/17/2021BarclaysReiterated RatingBuyLow
2/3/2021InvestecUpgradeHold ➝ BuyMedium
2/2/2021BarclaysUpgradeEqual Weight ➝ Overweight$56.00 ➝ $70.00N/A
9/18/2020Bank of AmericaUpgradeNeutral ➝ BuyLow
9/18/2020InvestecUpgradeSell ➝ HoldHigh
7/30/2020BarclaysBoost TargetEqual Weight$45.00 ➝ $53.00Low
4/21/2020Nomura InstinetReiterated RatingBuyMedium
1/9/2020CitigroupUpgradeSell ➝ BuyMedium
11/4/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
9/4/2019Credit Suisse GroupUpgradeUnderperform ➝ OutperformLow
7/1/2019MacquarieUpgradeNeutral ➝ OutperformLow
6/20/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ HoldLow
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$39.00Low
5/20/2019Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
2/4/2019CL KingUpgradeNeutral ➝ BuyLow
1/17/2019CitigroupDowngradeNeutral ➝ SellLow
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/11/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Dr. Reddy's Laboratories logo
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Read More

Today's Range

Now: $53.71
Low: $53.05
High: $53.82

50 Day Range

MA: $54.15
Low: $51.12
High: $57.03

52 Week Range

Now: $53.71
Low: $47.88
High: $65.86

Volume

213,618 shs

Average Volume

207,643 shs

Market Capitalization

$8.94 billion

P/E Ratio

22.76

Dividend Yield

0.60%

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Dr. Reddy's Laboratories?

The following Wall Street research analysts have issued research reports on Dr. Reddy's Laboratories in the last year: Barclays PLC, Credit Suisse Group AG, StockNews.com, and TheStreet.
View the latest analyst ratings for RDY.

What is the current price target for Dr. Reddy's Laboratories?

1 Wall Street analysts have set twelve-month price targets for Dr. Reddy's Laboratories in the last year. Their average twelve-month price target is $67.00, suggesting a possible upside of 25.3%. Barclays PLC has the highest price target set, predicting RDY will reach $67.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $67.00 for Dr. Reddy's Laboratories in the next year.
View the latest price targets for RDY.

What is the current consensus analyst rating for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RDY, but not buy more shares or sell existing shares.
View the latest ratings for RDY.

What other companies compete with Dr. Reddy's Laboratories?

How do I contact Dr. Reddy's Laboratories' investor relations team?

Dr. Reddy's Laboratories' physical mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company's listed phone number is 914049002900 and its investor relations email address is [email protected] The official website for Dr. Reddy's Laboratories is www.drreddys.com. Learn More about contacing Dr. Reddy‘s Laboratories investor relations.